Over the past decade, RAS oncogenic proteins have transitioned from being deemed
undruggable to having two clinically approved drugs, with several more in advanced stages …

Membrane protein-mediated resistance is a multidisciplinary challenge that spans fields
such as medicine, agriculture, and environmental science. Understanding its complexity and …

Summary KRAS G12D is the most frequently mutated oncogenic KRAS subtype in solid
tumors and remains undruggable in clinical settings. Here, we developed a high affinity …

This article presents a review of recent major advances in precision oncology and the future
implications of these advances, specifying the iterative progress achieved from the end of …

The leading cause of cancer deaths worldwide is attributed to non-small cell lung cancer
(NSCLC), necessitating a continual focus on improving the diagnosis and treatment of this …

Background The study summarizes the potential use of immunotherapy for BRAF-mutated
papillary thyroid cancer (PTC) by analyzing the immune profile of City of Hope PTC patient …

Mutated KRAS serves as the oncogenic driver in 30% of non-small cell lung cancers
(NSCLCs) and is associated with metastatic and therapy-resistant tumors. Focal Adhesion …

Several studies in the last few years have determined that, in contrast to the prevailing
dogma that drug resistance is simply due to Darwinian evolution—the selection of mutant …

Gingival fibroblasts are a significant source of paracrine signals required to maintain
periodontal homeostasis and to mediate pathological events linked to periodontitis and oral …

Adaptive resistance to conventional and targeted therapies remains one of the major
obstacles in effective management of cancer. Aberrant activation of key signaling …